Meeting
2016 ASCO Annual Meeting
A phase Ib study of lapatinib plus pegylated liposomal doxorubicin in patients with advanced HER2-positive breast cancer.
Authors
Andrea Rocca
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy
Andrea Rocca , Lorenzo Cecconetto , Alessandro Passardi , Elisabetta Melegari , Daniele Andreis , Manuela Monti , Roberta Maltoni , Samanta Sarti , Elisabetta Pietri , Alessio Schirone , Anna Fedeli , Caterina Donati , Oriana Nanni , Dino Amadori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
2009-012996-82
Citation
J Clin Oncol 34, 2016 (suppl; abstr 600)
DOI
10.1200/JCO.2016.34.15_suppl.600
Abstract #
600
Poster Bd #
88
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Phase I trial of pegylated liposomal doxorubicin and lapatinib in the treatment of metastatic breast cancer (MBC): Final results.
First Author: Mary E. Cianfrocca
Poster
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton
Poster
2015 ASCO Annual Meeting
A phase I trial and pharmacokinetic study of non-pegylated liposome-encapsulated doxorubicin citrate (NPLD) plus carboplatin in patients with recurrent gynecological and primary peritoneal tumors.
First Author: Andres Poveda
Poster
2014 ASCO Annual Meeting
Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).
First Author: Cristina Cruz Zambrano